TRT for Younger Men: Age-by-Age Clinical Guide (Under 30 to Over 65)

What Counts as Low Testosterone, and Who Gets Diagnosed Young?

Low testosterone is not just an older man's problem. The American Urological Association defines hypogonadism as a total testosterone consistently below 300 ng/dL on two separate fasting morning draws, combined with at least one clinical symptom such as reduced libido, fatigue, or loss of lean mass [1]. Data from the European Male Ageing Study found that roughly 5.1% of men aged 40-79 met full syndromic hypogonadism criteria, but younger cohorts are also affected [2].

A cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism estimated that approximately 2.1% of men between ages 20 and 39 have biochemical hypogonadism [3]. Causes in that age bracket differ sharply from those in older men. Klinefelter syndrome, pituitary adenomas, prior anabolic steroid use, obesity-related secondary hypogonadism, and idiopathic hypogonadotropic hypogonadism account for most cases in men under 35, whereas age-related Leydig cell decline dominates after 50 [4].

Before any testosterone is prescribed, clinicians must measure luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to separate primary from secondary hypogonadism, because the distinction dictates treatment. A man with low LH and low testosterone has a treatable pituitary or hypothalamic problem that may respond to clomiphene or gonadorelin without permanent suppression of his own axis [5].

TRT for Men Under 35: Fertility First

For men under 35, the fertility conversation comes before the prescription pad. Exogenous testosterone suppresses LH and FSH through negative feedback, reducing intratesticular testosterone to near zero and halting spermatogenesis in most men within 90 days [6]. A systematic review in Fertility and Sterility (2015) confirmed that azoospermia or severe oligospermia develops in over 90% of men on exogenous testosterone within 3-4 months [7].

The preferred first step is a fertility-sparing agent.

Clomiphene citrate (25-50 mg orally every other day or daily) blocks estrogen receptors at the hypothalamus, increasing endogenous LH and FSH, which in turn stimulates testicular testosterone production. A prospective study in BJU International (N=86) reported a mean total testosterone increase from 230 ng/dL to 612 ng/dL after 3 months of clomiphene, with no sperm suppression [8]. Clomiphene is off-label for this indication but widely used per Endocrine Society guidance [9].

Human chorionic gonadotropin (hCG) mimics LH directly at Leydig cells and can raise testosterone while preserving or even improving sperm counts. It is often combined with recombinant FSH when fertility restoration is the primary goal [10].

If a young man has confirmed completed his family, or if clomiphene and hCG fail to raise testosterone adequately after 3-6 months, standard TRT is appropriate. The Endocrine Society 2018 Clinical Practice Guideline states: "We suggest against starting testosterone therapy in patients who are actively trying to father a child" and recommends clomiphene or hCG as alternatives [9]. That quote reflects the consensus standard of care for this age group.

TRT for Men in Their 30s and 40s: The Most Common Treated Group

Men in their 30s and 40s represent the fastest-growing segment of TRT prescriptions in the United States. Between 2001 and 2011, testosterone prescriptions in men aged 40-49 tripled, and that trend has continued [11]. Many of these men have secondary hypogonadism driven by obesity, sleep apnea, or chronic stress rather than a fixed anatomical problem.

For this group, addressing root causes first matters. A 10% reduction in body weight can raise testosterone by 30-50 ng/dL in obese men with secondary hypogonadism [12]. Sleep apnea treatment alone has been shown to increase morning testosterone by a clinically meaningful margin in a randomized trial published in JAMA Internal Medicine [13].

When TRT is initiated in men aged 30-49, standard options include:

• Testosterone cypionate or enanthate 100-200 mg intramuscularly or subcutaneously every 7-14 days. Self-injection subcutaneously every 7 days (75-100 mg) produces more stable serum levels than biweekly IM dosing [14].
• Testosterone gels (1.62% AndroGel, Testim, Vogelxo) applied daily, titrated to a mid-normal serum target of 400-700 ng/dL.
• Testosterone pellets (Testopel) implanted subcutaneously every 3-6 months, delivering 150-450 mg depending on weight and dose response.

Monitoring in this group follows the same schedule as any TRT patient: serum testosterone, hematocrit, PSA (in men over 40), and lipids at 3 months, then every 6-12 months once stable [9].

TRT Over 50: Benefits, Risks, and the T-Trials Evidence

After age 50, testosterone declines at roughly 1-2% per year, and symptomatic hypogonadism becomes substantially more common [2]. The landmark Testosterone Trials (T-Trials), a coordinated set of seven randomized placebo-controlled trials in 788 men aged 65 and older with total testosterone below 275 ng/dL, provided the most rigorous evidence base for TRT in older men [15].

The sexual function trial showed a statistically significant improvement in sexual activity and desire. The physical function trial found modest improvements in walking distance. The vitality trial showed a small but significant benefit in energy and mood. The bone trial, published separately in NEJM (2017), demonstrated that testosterone treatment for 1 year increased volumetric bone mineral density at the lumbar spine by 7.5% vs. 0.6% placebo (P<0.001) [16].

The cardiovascular question dominated TRT research for over a decade after a 2010 trial was stopped early for excess cardiac events. The TRAVERSE trial (N=5,246, mean age 63.3 years, median follow-up 3.4 years) was designed specifically to resolve that question. Published in NEJM in 2023, it found non-inferiority for major adverse cardiovascular events (MACE) with testosterone undecanoate vs. placebo (hazard ratio 0.96 to 95% CI 0.78-1.17) [17]. Pulmonary embolism was numerically higher in the testosterone arm (41 vs. 26 events), a signal that warrants attention in men with prior venous thromboembolism [17].

For men over 50, the Endocrine Society recommends TRT when total testosterone is below 300 ng/dL confirmed on two occasions, symptoms are present, and no contraindications exist (prostate cancer, hematocrit above 54%, severe untreated sleep apnea, or active desire for fertility) [9].

TRT Over 65: Special Considerations for Older Adults

Age 65 brings additional variables. Polycythemia becomes more common because aging kidneys respond more vigorously to testosterone-stimulated erythropoietin. Hematocrit should be checked at baseline, at 3 months, and every 6 months thereafter. The FDA label for all testosterone products specifies dose reduction or temporary discontinuation if hematocrit exceeds 54% [18].

Bone health is a strong indication in this group. The T-Trials bone sub-study showed a 7.5% increase in lumbar spine volumetric BMD over 12 months [16], and a 2020 meta-analysis in JCEM confirmed that testosterone therapy significantly increases lumbar and femoral BMD in hypogonadal older men [19].

Falls and fracture risk benefit from the combination of improved muscle mass and bone density that TRT produces. A 12-month randomized trial found lean mass increased by 1.9 kg and fat mass decreased by 3.0 kg in men aged 60-75 on testosterone undecanoate vs. placebo [20].

PSA surveillance is essential. TRT does not cause prostate cancer, but it can accelerate the growth of occult disease. Baseline PSA testing is mandatory in men over 40, and a rise of more than 1.4 ng/mL from baseline over 12 months, or any single PSA above 4.0 ng/mL, should prompt urology referral before TRT is continued [9].

TRT for Bodybuilders: Medical TRT vs. Supraphysiologic Doping

Bodybuilders occupy a separate clinical category. True TRT targets a serum total testosterone of 400-700 ng/dL, the mid-normal range for a healthy adult male. Bodybuilding doses of exogenous testosterone, often 500-2 to 000 mg per week or higher when stacked with other anabolic steroids, produce supraphysiologic levels that fall entirely outside the definition of replacement [21].

The health risks at supraphysiologic doses are dose-dependent and well-documented. Left ventricular hypertrophy, reduced ejection fraction, polycythemia, severe dyslipidemia (HDL can fall to single-digit levels), and focal segmental glomerulosclerosis have all been reported in long-term anabolic-androgenic steroid (AAS) users [22]. A 2017 study in Circulation (N=140) found that former AAS users had a mean left ventricular ejection fraction of 52% vs. 63% in non-using controls, and 71% had plaque in at least one coronary artery segment [23].

When a bodybuilder presents with symptomatic hypogonadism after stopping AAS, the picture is post-cycle hypogonadism, a suppressed HPG axis that may recover over 6-18 months. The standard approach is either watchful waiting with serial testosterone measurements or a structured recovery protocol using hCG (500-2 to 000 IU every other day for 6-8 weeks) followed by clomiphene 25 mg daily for 6 weeks [24]. Jumping straight to TRT in this setting risks cementing a dependence that might have resolved.

The HealthRX clinical team uses a four-zone classification for men with prior AAS use who now present with low testosterone: Zone 1 (testosterone above 300 ng/dL, no symptoms, monitor only), Zone 2 (testosterone 200-299 ng/dL, symptoms present, trial of hCG or clomiphene for 12 weeks before TRT decision), Zone 3 (testosterone below 200 ng/dL, symptoms present, hCG for 6 weeks then reassess), and Zone 4 (testosterone below 200 ng/dL, no axis recovery after 6 months off AAS, initiate TRT). This framework reflects published recovery data from Rahnema et al. (2014) and the Endocrine Society guideline, adapted for post-AAS presentation.

TRT for Elite Athletes and WADA Status

Testosterone is a prohibited substance under the World Anti-Doping Agency (WADA) Prohibited List in both in-competition and out-of-competition categories for all sports under WADA jurisdiction [25]. This applies to all exogenous androgens regardless of dose or medical justification.

A Therapeutic Use Exemption (TUE) is theoretically available for athletes with confirmed hypogonadism, but WADA's Technical Document TD2021MRPL sets the reporting threshold for testosterone at 200 ng/mL in urine, and the longitudinal Athlete Biological Passport detects sustained elevation of the testosterone-to-epitestosterone ratio above 4:1 regardless of whether a TUE has been filed [26].

In practice, TUE approval for TRT is rare at the international level. The TUE criteria require that withholding the treatment produces significant health impairment, that no reasonable permitted alternative exists, and that the treatment does not produce performance enhancement beyond restoring normal physiological levels [25]. NCAA, USADA, and individual sport governing bodies follow analogous frameworks.

For competitive athletes at any level who are considering TRT, the practical advice is blunt: consult your anti-doping organization before starting any testosterone product. Any testosterone formulation, including topical gels and pellets, will produce a prohibited finding without an approved TUE.

How to Get an Accurate Diagnosis Before Starting TRT

A proper workup takes more than a single blood draw. Total testosterone varies by up to 30% across the day, peaking between 7 and 9 AM [27]. The Endocrine Society guideline requires two separate fasting morning samples at least 7 days apart before diagnosing hypogonadism [9].

The minimum diagnostic panel should include:

1. Total testosterone (two fasting morning draws)
2. Free testosterone (calculated via Vermeulen equation or equilibrium dialysis, not analog RIA)
3. LH and FSH to classify primary vs. secondary hypogonadism
4. Prolactin to screen for prolactinoma, especially if LH is low
5. Complete blood count (hematocrit baseline)
6. Metabolic panel, lipids
7. PSA (men over 40)
8. SHBG, because high SHBG can make total testosterone appear normal while free testosterone is deficient [28]

Men with secondary hypogonadism and LH below the normal range also need brain MRI with gadolinium contrast to exclude a pituitary adenoma before treatment starts [9].

Monitoring TRT: What Labs to Check and When

Starting TRT without a monitoring plan creates risk. The Endocrine Society 2018 guideline specifies the following schedule [9]:

• 3-6 weeks after initiation or dose change: serum testosterone (mid-cycle for injections), hematocrit, and symptom assessment.
• 3 months after starting: full panel including testosterone, hematocrit, PSA (men over 40), and lipids.
• Every 6-12 months once stable: same panel, plus bone density DEXA every 1-2 years in men with baseline osteopenia.

Target serum testosterone for most men on TRT is 400-700 ng/dL total. Doses should be adjusted to keep hematocrit below 54% and PSA velocity below 1.4 ng/mL per year [9].

Estradiol monitoring is standard practice in symptomatic men. TRT raises estradiol through peripheral aromatization. Estradiol above 40-50 pg/mL may cause gynecomastia, fluid retention, or mood changes, and can be managed with anastrozole 0.5-1 mg twice weekly when symptoms arise, though routine co-administration with every TRT prescription is not supported by current guidelines [9].

Age-by-Age TRT Summary

The table below consolidates the key protocol differences by decade.

| Age Group | Primary Concern | Preferred First Step | TRT Initiation Threshold | |---|---|---|---| | Under 30 | Fertility, reversible cause | Clomiphene or hCG | After fertility goals met or alternatives failed | | 30-44 | Root-cause optimization, fertility | Weight loss, sleep apnea Tx, then clomiphene | Confirmed hypogonadism, symptoms, no fertility plan | | 45-64 | Symptom burden, bone health | TRT is first-line if confirmed | Total T below 300 ng/dL x2, symptoms present | | 65 and older | Polycythemia risk, falls, fracture | TRT with close hematocrit monitoring | Same biochemical threshold, contraindications screened |

Formulation Choices Across Age Groups

Delivery method matters more than most patients realize. Injections of testosterone cypionate or enanthate produce peak-to-trough swings that some men find uncomfortable, with energy and mood high in the days after injection and lower before the next dose. Subcutaneous administration of the same ester at lower weekly doses (50-80 mg per week) produces flatter pharmacokinetics and is now a preferred approach in telehealth TRT practices [14].

Testosterone undecanoate (Aveed, Nebido) given every 10-14 weeks IM offers the flattest long-term pharmacokinetic profile of any injectable and is the formulation used in the T-Trials and TRAVERSE [15, 17]. Its disadvantage is that it requires in-office administration under FDA REMS because of rare risk of pulmonary oil microembolism [18].

Nasal testosterone (Natesto 5.5 mg per nostril three times daily) is the only formulation that does not consistently suppress the HPG axis, making it a viable option for younger men who want symptom relief while preserving some fertility [29]. A prospective study in Urology (N=54) confirmed that sperm concentrations remained within the normal range in most men after 6 months of Natesto [29].